John Mendlein leaves Mod­er­na for Flag­ship; Paul Sekhri to steer first xeno­trans­plan­ta­tion tri­als as eGe­n­e­sis CEO

John Mendlein is out at Mod­er­na just a year — a mo­men­tous year, no less, that saw Mod­er­na reap a $604 mil­lion IPO — af­ter be­com­ing pres­i­dent of the biotech uni­corn. The new role as ex­ec­u­tive part­ner at Flag­ship Pi­o­neer­ing brings him back to his “roots and pas­sion for cre­at­ing and grow­ing in­no­v­a­tive plat­form com­pa­nies,” he said in a state­ment. He will have stay an­oth­er six months as a con­sul­tant to Mod­er­na, where he led a cross-func­tion­al team prep­ping the com­pa­ny for the pub­lic mar­ket as well as cor­po­rate strat­e­gy, part­ner­ing, le­gal and in­tel­lec­tu­al prop­er­ty.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.